Department of Pharmacology, Key Laboratory of Environment and Genes Related to Diseases, School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, PR China.
J Ethnopharmacol. 2011 Sep 1;137(1):214-20. doi: 10.1016/j.jep.2011.05.008. Epub 2011 May 13.
Buyang Huanwu Decoction (BYHWD), a traditional Chinese medicine (TCM) formula, has been recognized as a clinical treatment for coronary heart disease (CHD) with qi deficiency and blood stasis syndrome. The effects of BYHWD on hemorheological disorders and energy metabolism in CHD with qi deficiency and blood stasis syndrome are still unclear.
To investigate whether the ameliorative effects of BYHWD on CHD rats with qi deficiency and blood stasis syndrome are associated with the regulation of hemorheological disorders and energy metabolism.
The rats were lavaged with 25.68, 12.84 and 6.42 g/kg BYHWD (g weight of mixed crude drugs/kg body weight), respectively, once a day for 21 days. The body weight, exhaustive swimming time and tongue characters were observed and recorded. The whole blood viscosity and plasma viscosity were determined by hematology analyzer. The level of fibrinogen (Fbg) in plasma was determined by using Fbg assay kit. The platelet aggregation induced by adenosine diphosphatase was measured by semi-automatic whole blood platelet analyzer. The level of blood glucose (BG) was determined by LifeScan. The activity of Na(+)-K(+)-ATPase in heart tissues was detected by spectrophotometer.
BYHWD improved the exterior signs of qi deficiency and blood stasis syndrome in rats with CHD, including the body weight, exhaustive swimming time and tongue quality. The whole blood viscosity in rats treated with 25.68 g/kg BYHWD decreased at the shear rate of 10s(-1) (P<0.05) and the plasma viscosity decreased in rats treated with 25.68 and 12.84 g/kg BYHWD (P<0.05). The plasma Fbg level and the platelet aggregation decreased in rats treated with 25.68 g/kg BYHWD (P<0.01). The results also revealed that the BG level decreased and the Na(+)-K(+)-ATPase activity in heart tissues increased in rats treated with 25.68 and 12.84 g/kg BYHWD (P<0.01).
The results suggest that the ameliorative effects of BYHWD on CHD rats with qi deficiency and blood stasis syndrome are mediated by the improvement of hemorheological disorders and energy metabolism.
补阳还五汤（BYHWD）是一种中药方剂，已被认可为治疗气虚血瘀型冠心病的临床治疗方法。BYHWD 对气虚血瘀型冠心病血液流变学紊乱和能量代谢的影响尚不清楚。
探讨补阳还五汤对气虚血瘀型冠心病大鼠的改善作用是否与血液流变学紊乱和能量代谢的调节有关。
分别灌胃 25.68、12.84 和 6.42g/kg BYHWD（混合生药重量/公斤体重），每天 1 次，共 21 天。观察并记录体重、力竭游泳时间和舌象。血液流变仪测定全血粘度和血浆粘度。纤维蛋白原（Fbg）测定试剂盒测定血浆 Fbg 水平。半自动化全血血小板分析仪测定血小板聚集诱导的二磷酸腺苷。LifeScan 测定血糖（BG）水平。分光光度计检测心脏组织中 Na(+)-K(+)-ATP 酶的活性。
补阳还五汤改善了气虚血瘀型冠心病大鼠的外在征象，包括体重、力竭游泳时间和舌象。灌胃 25.68g/kg BYHWD 可降低大鼠 10s(-1)剪切率下的全血粘度（P<0.05），灌胃 25.68 和 12.84g/kg BYHWD 可降低大鼠血浆粘度（P<0.05）。灌胃 25.68g/kg BYHWD 可降低大鼠血浆 Fbg 水平和血小板聚集（P<0.01）。结果还表明，灌胃 25.68 和 12.84g/kg BYHWD 可降低大鼠血糖（BG）水平，增加心脏组织中 Na(+)-K(+)-ATP 酶的活性（P<0.01）。
研究结果表明，补阳还五汤对气虚血瘀型冠心病大鼠的改善作用是通过改善血液流变学紊乱和能量代谢来介导的。
